Problems of Cancer Treatment. Part 2. Treatment Based on Modification of Anticancer Immunological Responses in Therapy

[1] Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE, Rosenberg SA. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009; 114: 1537-154410.1182/blood-2008-12-195792Search in Google Scholar

[2] Ansell SM. Nivolumab in the treatment of Hodgkin lymphoma. Clin Canc Res 2016; 23 (7): 1-5Search in Google Scholar

[3] Baughman RP. Technical aspects of bronchoalveolar lavage: recommendations for a standard procedure. Semin.Respir Crit Care Med 2007; 28: 475-48510.1055/s-2007-991520Search in Google Scholar

[4] Brandhorst G, Petrova DT, Weigand S, Eberle C, von AN, Schmitz J, Schultze FC, Raddatz D, Karaus M, Oellerich M, Walson PD. Lack of correlation between Treg quantification assays in inflammatory bowel disease patients. World J Gastroenterol. 2015; 21: 3325-332910.3748/wjg.v21.i11.3325Search in Google Scholar

[5] Butts C, Socinski MA, Mitchell PL, Thatcher N, Havel L, Krzakowski M, Nawrocki S, Ciuleanu TE, Bosquee L, Trigo JM, Spira A, Tremblay L, Nyman J, Ramlau R, Wickart-Johansson G, Ellis P, Gladkov O, Pereira JR, Eberhardt WE, Helwig C, Schroder A, Shepherd FA. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2014; 15: 59-6810.1016/S1470-2045(13)70510-2Search in Google Scholar

[6] Chcialowski A, Chorostkowska-Wynimko J, Fal A, Pawlowicz R, Domagala-Kulawik J. Recommendation of the Polish Respiratory Society for bronchoalveolar lavage (BAL) sampling, processing and analysis methods. Pneumonol.Alergol.Pol. 2011; 79: 75-98Search in Google Scholar

[7] Chmielowicz B, Obojski A, Barczyk A, Sozanska E, Kycler Z, Demkow U, Domagala-Kulawik J. [Methodology of induced sputum induction and processing--recommendation of Polish Respiratory Society]. Pneumonol.Alergol.Pol. 2008; 76: 378-394Search in Google Scholar

[8] Dabrowska M, Grubek-Jaworska H, Domagala-Kulaw ik J, Bartoszewicz Z, Kondracka A, Krenke R, Nejman P, Chazan R. [Diagnostic usefulness of selected tumor markers (CA125, CEA, CYFRA 21-1) in bronchoalveolar lavage fluid in patients with non-small cell lung cancer]. Pol.Arch.Med.Wewn. 2004; 111: 659-665Search in Google Scholar

[9] Domagala-Kulawik J. BAL in the diagnosis of smoking-related interstitial lung diseases: review of literature and analysis of our experience. Diagn.Cytopathol. 2008; 36: 909-91510.1002/dc.2094418855907Search in Google Scholar

[10] Domagala-Kulawik J. Effects of cigarette smoke on the lung and systemic immunity. J.Physiol Pharmacol. 2008; 59 Suppl 6: 19-34Search in Google Scholar

[11] Domagala-Kulawik J. The role of the immune system in non-small cell lung carcinoma and potential for therapeutic intervention. Transl.Lung Cancer Res. 2015; 4: 177-190Search in Google Scholar

[12] Domagala-Kulawik J, Droszcz P, Kraszewska I, Chazan R. Expression of Fas antigen in the cells from bronchoalveolar lavage fluid (BALF). Folia Histochem.Cytobiol. 2000; 38: 185-188Search in Google Scholar

[13] Domagala-Kulawik J, Hoser G, Dabrowska M, Safianowska A, Chazan R. CD4+/CD25+ cel l s in systemic inflammation in COPD. Scand.J.Immunol. 2011; 73: 59-65Search in Google Scholar

[14] Domagala-Kulawik J, Hoser G, Doboszynska A, Kawiak J, Droszcz W. [Phenotype of lymphocytes in bronchoalveolar lavage fluid of patients with lung fibrosis in the course of scleroderma]. Pneumonol. Alergol.Pol. 1995; 63: 382-388Search in Google Scholar

[15] Domagala-Kulawik J, Hoser G, Safianowska A, Grubek-Jaworska H, Chazan R. El evat ed TGF- -beta1 concentration in bronchoalveolar lavage fluid from patients with primary lung cancer. Arch. Immunol Ther.Exp.(Warsz.) 2006; 54: 143-147Search in Google Scholar

[16] Domagala-Kulawik J, Maskey-Warzecowska M. T-regulatory cells in COPD or tumour environment. Eur.Respir.J. 2009; 34: 284-286Search in Google Scholar

[17] Domagala-Kulawik J, Osinska I. [Immune alterations in lung cancer - the new therapeutic approach]. Pneumonol.Alergol.Pol. 2014; 82: 286-299Search in Google Scholar

[18] Domagala-Kulawik J, Osinska I, Hoser G. Mechanisms of immune response regulation in lung cancer. Transl.Lung Cancer Res. 2014; 3: 15-22Search in Google Scholar

[19] Dummer CD, Carpio VN, Goncalves LF, Manfro RC, Veronese FV. FOXP3+ regulatory T cells: from suppression of rejection to induction of renal allograft tolerance. Transpl.Immunol. 2012; 26: 1-10Search in Google Scholar

[20] Duraiswamy J, Kaluza KM, Freeman GJ, Coukos G. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res. 2013; 73: 3591-360310.1158/0008-5472.CAN-12-4100368691323633484Search in Google Scholar

[21] Fan F, Samuel S, Evans KW, Lu J, Xia L, Zhou Y, Sceusi E, Tozzi F, Ye XC, Mani SA, Ellis LM. Overexpression of snail induces epithelial-mesenchymal transition and a cancer stem cell-like phenotype in human colorectal cancer cells. Cancer Med. 2012; 1: 5-1610.1002/cam4.4354443023342249Search in Google Scholar

[22] Fridman WH, Remark R, Goc J, Giraldo NA, Becht E, Hammond SA, Damotte D, Dieu-Nosjean MC, Sautes-Fridman C. The immune microenvironment: a major player in human cancers. Int.Arch. Allergy Immunol. 2014; 164: 13-2610.1159/00036233224852691Search in Google Scholar

[23] Frydecka I, Kosmaczewska A, Bocko D, Ciszak L, Wolowiec D, Kuliczkowski K, Kochanowska I. Alterations of the expression of T-cell-related costimulatory CD28 and downregulatory CD152 (CTLA-4) molecules in patients with B-cell chronic lymphocytic leukaemia. Br.J Cancer 2004; 90: 2042-204810.1038/sj.bjc.6601833240946615138491Search in Google Scholar

[24] Galon J, Pages F, Marincola FM, Thurin M, Trinchieri G, Fox BA, Gajewski TF, Ascierto PA. The immune score as a new possible approach for the classification of cancer. J Transl.Med. 2012; 10: 1Search in Google Scholar

[25] Giavina-Bianchi M, Giavina-Bianchi P, Sotto MN, Muzikansky A, Kalil J, Festa-Neto C, Duncan LM. Increased NY-ESO-1 expression and reduced infiltrating CD3+ T cells in cutaneous melanoma. J Immunol.Res. 2015; 2015: 761378Search in Google Scholar

[26] Giraldo NA, Becht E, Vano Y, Sautes-Fridman C, Fridman WH. The immune response in cancer: from immunology to pathology to immunotherapy. Virchows Arch. 2015; 467: 127-13510.1007/s00428-015-1787-726077464Search in Google Scholar

[27] Hai J, Sakashita S, Allo G, Ludkovski O, Ng C, Shepherd FA, Tsao MS. Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non-Small Cell Lung Cancer Xenograft Models. J Thorac.Oncol. 2015; 10: 1172-1180Search in Google Scholar

[28] Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, Dronca R, Gangadhar TC, Patnaik A, Zarour H, Joshua AM, Gergich K, Elassaiss-Schaap J, Algazi A, Mateus C, Boasberg P, Tumeh PC, Chmielowski B, Ebbinghaus SW, Li XN, Kang SP, Ribas A. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N.Engl.J Med. 2013; 369: 134-144Search in Google Scholar

[29] Hermanowicz-Salamon J, Domagala-Kulawik J, Maskey-Warzechowska M, Chazan R. [Macrophage phenotype in induced sputum in asthma subjects]. Pneumonol.Alergol.Pol. 2006; 74: 101-105Search in Google Scholar

[30] Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbe C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ. Improved survival with ipilimumab in patients with metastatic melanoma. N.Engl.J Med. 2010; 363: 711-723Search in Google Scholar

[31] Hoser G, Domagala-Kulawik J, Droszcz P, Droszcz W, Kawiak J. Lymphocyte subsets differences in smokers and nonsmokers with primary lung cancer: a flow cytometry analysis of bronchoalveolar lavage fluid cells. Med.Sci.Monit. 2003; 9: BR310-BR315Search in Google Scholar

[32] Hoser G, Kawiak J, Domagala-Kulawik J, Kopinski P, Droszcz W. Fl ow cytometric evaluation of lymphocyte subpopulations in BALF of healthy smokers and nonsmokers. Folia Histochem.Cytobiol. 1999; 37: 25-30Search in Google Scholar

[33] Hou TZ, Qureshi OS, Wang CJ, Baker J, Young SP, Walker LS, Sansom DM. A transendocytosis model of CTLA-4 function predicts its suppressive behavior on regulatory T cells. J Immunol. 2015; 194: 2148-215910.4049/jimmunol.1401876452273625632005Search in Google Scholar

[34] Hus I, Kawiak J, Tabarkiewicz J, Radej S, Hoser G, Bojarska-Junak A, Schmitt M, Giannopoulos K, Dmoszynska A, Rolinski J. Immunotherapy with irradiated autologous leukemic cells in patients with B-CLL in early stages. Oncol.Rep. 2008; 20: 443-451Search in Google Scholar

[35] Hus I, Schmitt M, Tabarkiewicz J, Radej S, Wojas K, Bojarska-Junak A, Schmitt A, Giannopoulos K, Dmoszynska A, Rolinski J. Vaccination of B-CLL patients with autologous dendritic cells can change the frequency of leukemia antigen-specific CD8+ T cells as well as CD4+CD25+FoxP3+ regulatory T cells toward an antileukemia response. Leukemia 2008; 22: 1007-101710.1038/leu.2008.2918323802Search in Google Scholar

[36] Kawalec M, Jakobisiak M, Skorski T, Kawiak J. Immunogenicity of cyclophosphamide-treated leukaemia cells. Folia Biol.(Praha) 1982; 28: 334-343Search in Google Scholar

[37] Kawalec M, Skorski T, Kawiak J. Successful chemoimmunotherapy of murine L1210 lymphatic leukemia with cyclophosphamide and mafosfamide-treated leukemia cells. Invest New Drugs 1988; 6: 169-17210.1007/BF001753933192382Search in Google Scholar

[38] Kawiak J, Hus I.Rolinski J, Tabarkiewicz J, Wojas K, Kosek A, Bojarska-Junak A, Kowal M, Górska M, Dmoszyńska A Immunotherapy of B-cell Patients with autologous Irradiated Leukemic cells and BCG, Pol J Environmental Studies supl II, 2005; 14: 187-191.Search in Google Scholar

[39] Kerr KM, Tsao MS, Nicholson AG, Yatabe Y, Wistuba II, Hirsch FR. Pr ogrammed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art? J Thorac.Oncol. 2015; 10: 985-989Search in Google Scholar

[40] Kruger C, Greten TF, Korangy F. Immune based therapies in cancer. Histol.Histopathol. 2007; 22: 687-696Search in Google Scholar

[41] Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996; 271: 1734-173610.1126/science.271.5256.17348596936Search in Google Scholar

[42] Lin X, Chen M, Liu Y, Guo Z, He X, Brand D, Zheng SG. Advances in distinguishing natural from induced Foxp3(+) regulatory T cells. Int.J Clin.Exp.Pathol. 2013; 6: 116-123Search in Google Scholar

[43] Liu H, Zhang T, Ye J, Li H, Huang J, Li X, Wu B, Huang X, Hou J. Tumor-infiltrating lymphocytes predict response to chemotherapy in patients with advance non-small cell lung cancer. Cancer Immunol. Immunother. 2012; 61: 1849-185610.1007/s00262-012-1231-722456757Search in Google Scholar

[44] Liu J, Lluis A, Illi S, Layland L, Olek S, von ME, Schaub B. T r egulatory cells in cord blood-FOXP3 demethylation as reliable quantitative marker. PLoS.One. 2010; 5: e1326710.1371/journal.pone.0013267295350520967272Search in Google Scholar

[45] Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, Beck A, Miller A, Tsuji T, Eppolito C, Qian F, Lele S, Shrikant P, Old LJ, Odunsi K. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc.Natl.Acad.Sci.U.S.A 2010; 107: 7875-7880Search in Google Scholar

[46] McClymont SA, Putnam AL, Lee MR, Esensten JH, Liu W, Hulme MA, Hoffmuller U, Baron U, Olek S, Bluestone JA, Brusko TM. Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes. J Immunol. 2011; 186: 3918-392610.4049/jimmunol.1003099309194321368230Search in Google Scholar

[47] Moschella F, Torelli GF, Valentini M, Urbani F, Buccione C, Petrucci MT, Natalino F, Belardelli F, Foa R, Proietti E. Cyclophosphamide induces a type I interferon-associated sterile inflammatory response signature in cancer patients’ blood cells: implications for cancer chemoimmunotherapy. Clin. Cancer Res. 2013; 19: 4249-4261Search in Google Scholar

[48] Neller MA, Lopez JA, Schmidt CW. Antigens for cancer immunotherapy. Semin.Immunol. 2008; 20: 286-295Search in Google Scholar

[49] Okamura T, Fujio K, Sumitomo S, Yamamoto K. Roles of LAG3 and EGR2 in regulatory T cells. Ann. Rheum.Dis. 2012; 71 Suppl 2: i96-10010.1136/annrheumdis-2011-20058822460149Search in Google Scholar

[50] Okamura T, Sumitomo S, Morita K, Iwasaki Y, Inoue M, Nakachi S, Komai T, Shoda H, Miyazaki J, Fujio K, Yamamoto K. TGF-beta3-expressing CD4+CD25(-)LAG3+ regulatory T cells control humoral immune responses. Nat.Commun. 2015; 6: 6329Search in Google Scholar

[51] Osinska I, Domagala-Kulawik J. [Bronchoalveolar lavage in lung cancer-diagnostic value and assessment of the anti-cancer immune response]. Postepy Hig.Med.Dosw.(Online.) 2013; 67: 1119-1127Search in Google Scholar

[52] Ott PA, Hodi FS, Buchbinder EI. Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data. Front Oncol. 2015; 5: 20210.3389/fonc.2015.00202458511226442214Search in Google Scholar

[53] Ott PA, Hodi FS, Robert C. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin.Cancer Res. 2013; 19: 5300-5309Search in Google Scholar

[54] Palucka K, Banchereau J. Dendritic-cell-based therapeutic cancer vaccines. Immunity. 2013; 39: 38-4810.1016/j.immuni.2013.07.004378867823890062Search in Google Scholar

[55] Pan Q, Li Q, Liu S, Ning N, Zhang X, Xu Y, Chang AE, Wicha MS. Concise Review: Targeting Cancer Stem Cells Using Immunologic Approaches. Stem Cells 2015; 33: 2085-209210.1002/stem.2039447820425873269Search in Google Scholar

[56] Perez-Gracia JL, Labiano S, Rodriguez-Ruiz ME, Sanmamed MF, Melero I. Orchestrating immune check-point blockade for cancer immunotherapy in combinations. Curr.Opin.Immunol. 2014; 27: 89-97Search in Google Scholar

[57] Pizzurro GA, Tapia IJ, Sganga L, Podhajcer OL, Mordoh J, Barrio MM. Cytokine-enhanced maturation and migration to the lymph nodes of a human dying melanoma cell-loaded dendritic cell vaccine. Cancer Immunol.Immunother. 2015; 64(11): 1393-406.10.1007/s00262-015-1743-z26197849Search in Google Scholar

[58] Postow MA, Callahan MK, Wolchok JD. Immune Checkpoint Blockade in Cancer Therapy. J Clin. Oncol. 2015; 33: 1974-1982Search in Google Scholar

[59] Putnam AL, Safinia N, Medvec A, Laszkowska M, Wray M, Mintz MA, Trotta E, Szot GL, Liu W, Lares A, Lee K, Laing A, Lechler RI, Riley JL, Bluestone JA, Lombardi G, Tang Q. Cl inical grade manufacturing of human alloantigen-reactive regulatory T cells for use in transplantation. Am.J Transplant. 2013; 13: 3010-3020Search in Google Scholar

[60] Radojcic V, Bezak KB, Skarica M, Pletneva MA, Yoshimura K, Schulick RD, Luznik L. Cycl ophosphamide resets dendritic cell homeostasis and enhances antitumor immunity through effects that extend beyond regulatory T cell elimination. Cancer Immunol.Immunother. 2010; 59: 137-14810.1007/s00262-009-0734-3310386719590872Search in Google Scholar

[61] Rolinski J, Hus I. Br eaking immunotolerance of tumors: a new perspective for dendritic cell therapy. J Immunotoxicol. 2014; 11: 311-31810.3109/1547691X.2013.86509424495309Search in Google Scholar

[62] Ruben JM, van den Ancker W, Bontkes HJ, Westers TM, Hooijberg E, Ossenkoppele GJ, de Gruijl TD, van de Loosdrecht AA. Apoptotic blebs from leukemic cells as a preferred source of tumor-associated antigen for dendritic cell-based vaccines. Cancer Immunol.Immunother. 2014; 63: 335-34510.1007/s00262-013-1515-624384837Search in Google Scholar

[63] Sabbatini P, Tsuji T, Ferran L, Ritter E, Sedrak C, Tuballes K, Jungbluth AA, Ritter G, Aghajanian C, Bell-McGuinn K, Hensley ML, Konner J, Tew W, Spriggs DR, Hoffman EW, Venhaus R, Pan L, Salazar AM, Diefenbach CM, Old LJ, Gnjatic S. Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients. Clin.Cancer Res. 2012; 18: 6497-6508Search in Google Scholar

[64] Saha A, Chatterjee SK. Combination of CTL-associated antigen-4 blockade and depletion of CD25 regulatory T cells enhance tumour immunity of dendritic cell-based vaccine in a mouse model of colon cancer. Scand.J Immunol. 2010; 71: 70-82Search in Google Scholar

[65] Salvi S, Fontana V, Boccardo S, Merlo DF, Margallo E, Laurent S, Morabito A, Rijavec E, Dal Bello MG, Mora M, Ratto GB, Grossi F, Truini M, Pistillo MP. Evaluation of CTLA-4 expression and relevance as a novel prognostic factor in patients with non-small cell lung cancer. Cancer Immunol. Immunother. 2012; 61: 1463-147210.1007/s00262-012-1211-y22318401Search in Google Scholar

[66] Schmitt EG, Williams CB. Generation and function of induced regulatory T cells. Front Immunol. 2013; 4: 152Search in Google Scholar

[67] Senovilla L, Vacchelli E, Galon J, Adjemian S, Eggermont A, Fridman WH, Sautes-Fridman C, Ma Y, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Prognostic and predictive value of the immune infiltrate in cancer. Oncoimmunology. 2012; 1: 1323-134310.4161/onci.22009351850523243596Search in Google Scholar

[68] Shih K, Arkenau HT, Infante JR. Cl inical impact of checkpoint inhibitors as novel cancer therapies. Drugs 2014; 74: 1993-201310.1007/s40265-014-0305-6422473725344022Search in Google Scholar

[69] Shrimali RK, Janik JE, Abu-Eid R, Mkrtichyan M, Khleif SN. Programmed death-1 & its ligands: promising targets for cancer immunotherapy. Immunotherapy. 2015; 7: 777-79210.2217/imt.15.4926250412Search in Google Scholar

[70] Skirecki T, Hoser G, Domagala-Kulawik J, Kawiak J. Characterization of a new small cell lung cancer (SCLC) cell line STP54 derived from a metastatic bioptate of a combined type of SCLC with Non-SCLC component. Folia Histochem.Cytobiol. 2009; 47: 111-115Search in Google Scholar

[71] Skorski T, Kawalec M, Kawiak J. Mechanisms of immunological response induced in CD2F1 mice by administration of semisyngeneic L 1210 leukemia cells treated with cyclophosphamide. Immunol. Invest 1987; 16: 33-43Search in Google Scholar

[72] Stadler S, Weina K, Gebhardt C, Utikal J. New therapeutic options for advanced non-resectable malignant melanoma. Adv.Med.Sci. 2015; 60: 83-88Search in Google Scholar

[73] Sundar R, Soong R, Cho BC, Brahmer JR, Soo RA. Immunotherapy in the treatment of non-small cell lung cancer. Lung Cancer 2014; 85: 101-10910.1016/j.lungcan.2014.05.005433277824880938Search in Google Scholar

[74] Takiguchi Y, Sekine I, Iwasawa S, Kurimoto R, Tatsumi K. Chronic obstructive pulmonary disease as a risk factor for lung cancer. World J Clin.Oncol. 2014; 5: 660-666Search in Google Scholar

[75] Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, Chen S, Klein AP, Pardoll DM, Topalian SL, Chen L. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci.Transl.Med. 2012; 4: 127ra3710.1126/scitranslmed.3003689356852322461641Search in Google Scholar

[76] van Montfoort N, van der Aa E, Woltman AM. Understanding MHC class I presentation of viral antigens by human dendritic cells as a basis for rational design of therapeutic vaccines. Front Immunol. 2014; 5: 18210.3389/fimmu.2014.00182400594824795724Search in Google Scholar

[77] Wang C, Yu X, Wang W. A meta-analysis of efficiacy and safety of antibodies targeting PD-1/PD-L1 in treatment of advanced nonsmall cell lung cancer. Medicine 2016; 95: 5210.1097/MD.0000000000005539520754528033249Search in Google Scholar

[78] Velcheti V, Schalper KA, Carvajal DE, Anagnostou VK, Syrigos KN, Sznol M, Herbst RS, Gettinger SN, Chen L, Rimm DL. Pr ogrammed death ligand-1 expression in non-small cell lung cancer. Lab Invest 2014; 94: 107-11610.1038/labinvest.2013.130612525024217091Search in Google Scholar

[79] Wojas J, Pajtasz-Piasecka E. [Dendritic cell-regulatory T-cell interaction]. Postepy Hig.Med.Dosw. (Online.) 2010; 64: 167-174Search in Google Scholar

[80] Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, Burke MM, Caldwell A, Kronenberg SA, Agunwamba BU, Zhang X, Lowy I, Inzunza HD, Feely W, Horak CE, Hong Q, Korman AJ, Wigginton JM, Gupta A, Sznol M. Nivolumab plus ipilimumab in advanced melanoma. N.Engl.J Med. 2013; 369: 122-133Search in Google Scholar

[81] Woo SR, Turnis ME, Goldberg MV, Bankoti J, Selby M, Nirschl CJ, Bettini ML, Gravano DM, Vogel P, Liu CL, Tangsombatvisit S, Grosso JF, Netto G, Smeltzer MP, Chaux A, Utz PJ, Workman CJ, Pardoll DM, Korman AJ, Drake CG, Vignali DA. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 2012; 72: 917-92710.1158/0008-5472.CAN-11-1620328815422186141Search in Google Scholar

[82] Yao S, Zhu Y, Chen L. Advances in targeting cell surface signalling molecules for immune modulation. Nat.Rev.Drug Discov. 2013; 12: 130-14610.1038/nrd3877369857123370250Search in Google Scholar